Hence, targeting SV2B may result in fewer toxic side effects than targeting the NF‐κB pathway.[40] In conclusion, we suggest targeting SV2B or the NF‐κB pathway as novel therapeutic strategies for TFE3‐RCC. This evidence concerns the gene NFKB1 and renal cell carcinoma.